In this study, we aimed to investigate the prevalence of fibromyalgia syndrome (FMS) in patients with metabolic syndrome (MetS) and its effects on sleep quality and quality of life (QoL). Methods: The study included a total of 84 (56 females, 28 males) patients with MetS, with a mean age of 57.5 (34-74) years and mean body mass index of 32.5 (25-48.9) kg/m2. MetS was defined according to the National Cholesterol Education Program Adult Treatment Panel III criteria. The FMS diagnosis was made based on the 2013 American College of Rheumatology Alternative Criteria. QoL and sleep quality were evaluated by the Short Form 36 (SF-36) and the Pittsburgh Sleep Quality Index, respectively. Results: All patients had diabetes mellitus and were obese or overweight. Of all patients, 73.8% had poor sleep quality and 51.2% had FMS. Patients with both MetS and FMS had a statistically significant female predominance (p<0.001). Impaired sleep was present in 62.9% of patients with both MetS and FMS and 37.1% of patients with MetS only (p<0.001). All SF-36 domain scores were statistically significantly lower in the MetS+FMS group than in the MetS group (p<0.001) Conclusion: The frequency of FMS is high in patients with MetS. Sleep quality and QoL are impaired in the presence of FMS or MetS alone. The co-presence of these conditions causes poorer sleep quality and worse QoL. FMS should be considered in the treatment and followup of patients with MetS.
Objective: This study aims to determine whether neuropathic pain (NP) presence affects sleep quality in patients with axial spondyloarthritis (AxSpA). Materials and Methods: Demographic data of the patients were documented. The patient's NP was evaluated with painDETECT questionnaire. Pittsburgh Sleep Quality Index (PSQI), Ankylosing Spondylitis Quality of Life (AsQoL), Ankylosing Spondylitis Disease Activity Score (ASDAS-CRP), and visual analog scale (VAS) were used to evaluate sleep quality, quality of life (QoL), pain severity and disease activity, respectively. Results: Among the 108 patients who participated in the researh, 51 were female and 57 were male. NP was found in 41.7% of them. 65.7% Of all patients had a sleep disorder. AxSpA patients with NP had a statistically significant higher VAS-activity, VAS-night, and VAS-rest scores (p<0.001, p<0.001, p=0.002, respectively). They also had higher ASQoL scores and higher disease activity. (p=0.008, p=0.012, respectively). Although impaired sleep was detected in 71.1% of AxSpA patients with NP, it was present in 61.9% of AxSpA patients without NP, and we didn’t find a statistically significant difference (p=0.32). Total painDETECT scores were correlated with PSQI ASQoL, and VAS scores (p< 0.001). But there was no correlation with ASDAS-CRP scores (p=0.57). Conclusion: A large majority of AxSpA patients have a sleep problem, independent of the presence of NP. Not only targeting the inflammatory pain but also targeting NP and sleep disorder together in the follow-up of patients with AxSpA will improve QoL.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.